KINTOR PHARMA-B (09939) released its Monthly Return for the period ended 28 February 2026. According to the announcement, the authorized share capital remained at 700.00 million ordinary shares (USD 0.0001 par value each), totaling 0.07 million USD in authorized capital, with no changes from the previous month.

The total number of issued shares stood at 498.66 million, with no treasury shares and no change compared to the preceding month. The company confirmed compliance with the applicable 25% public float requirement. There were no outstanding share options, warrants, convertibles, or other agreements to issue additional shares during the reporting period.